Materials and Methods: The study group consisted of women aged 19 to 64 years diagnosed as CM according to current International Headache Society (IHS) criteria, and OAB using the OAB-V8 (Overactive Bladder Inquiry Form - V8) and ICIQ-SF (International Consultation on Incontinence Questionnaire Short Form) forms as well as clinical evaluation in the neurology and urology clinics. 63 patients informed and agreed to enter the study were started migraine prophylaxis and evaluated after 6 months for comparison of pre-treatment and post-treatment VPS (visual pain scale), OAB-V8, and the ICIQ-SF scores. Flunarizine, topiramate, venlafaxine and propranolol were used in the treatment of patients.

Results: The mean age of 63 women included in the study was 39.15 ± 8.74 (19-64) years. The mean Body Mass Index (BMI) of the patients was determined as 25.41 ± 3.64 (16.4-35.6) kg/m2. After migraine prophylaxis, VPS, OAB-V8 and ICIQ-SF scores decreased significantly in the entire patient group (p<0.05). Statistically significant changes were found in the values of VPS, OAB-V8 and ICIQ-SF in the topiramate or propranolol treated groups. In the flunarizine group, there was a significant statistical response in the VPS and OAB-V8 scores, while there were no significant changes in the ICIQ-SF and OAB-V8 scores in the venlafaxinetreated group.

Conclusion: The beneficial effect of migraine prophylaxis on OAB symptoms support somewhat shared etiopathogenesis for both disorders. However, the series is small and considering the involvement of multifactorial factors and complex physiopathology for both disorders further studies are necessary to reveal the underlying mechanisms and clinical impacts.